IN2012DN02861A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02861A IN2012DN02861A IN2861DEN2012A IN2012DN02861A IN 2012DN02861 A IN2012DN02861 A IN 2012DN02861A IN 2861DEN2012 A IN2861DEN2012 A IN 2861DEN2012A IN 2012DN02861 A IN2012DN02861 A IN 2012DN02861A
- Authority
- IN
- India
- Prior art keywords
- relates
- pharmaceutical compositions
- compositions
- igf
- insulin
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 102000013275 Somatomedins Human genes 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26185909P | 2009-11-17 | 2009-11-17 | |
| PCT/EP2010/006996 WO2011060922A1 (en) | 2009-11-17 | 2010-11-17 | Formulation for hgh and rhigf-1 combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02861A true IN2012DN02861A (enrdf_load_stackoverflow) | 2015-07-24 |
Family
ID=43661042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2861DEN2012 IN2012DN02861A (enrdf_load_stackoverflow) | 2009-11-17 | 2010-11-17 |
Country Status (14)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2532089T3 (es) | 2005-06-02 | 2015-03-24 | Ipsen Biopharmaceuticals, Inc. | GH e IGF-1 para el tratamiento de trastornos del crecimiento |
| JP6363949B2 (ja) * | 2011-07-25 | 2018-07-25 | サンド アクチェンゲゼルシャフト | 少なくとも中性塩および生物薬学的タンパク質を含む、水性製剤 |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| IL287947B2 (en) | 2014-10-23 | 2024-08-01 | Amgen Inc | Reducing viscosity of pharmaceutical formulations |
| WO2016115561A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Formulations and screening of biological therapeutic agents |
| AU2016218759B2 (en) * | 2015-02-11 | 2021-11-25 | Gmax Biopharm Llc. | Stabilized solution preparation of pharmaceutical GLP-1R antibody fusion protein |
| US20190060241A1 (en) * | 2016-04-13 | 2019-02-28 | Medimmune, Llc | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| US20210087236A1 (en) * | 2016-08-15 | 2021-03-25 | The University Of North Carolina At Chapel Hill | Tardigrade disordered proteins as protein stabilizers |
| US11459401B2 (en) | 2016-10-06 | 2022-10-04 | Amgen Inc. | Reduced viscosity protein pharmaceutical formulations |
| US10953074B2 (en) * | 2017-01-08 | 2021-03-23 | Richard D. Lippman | Composition and method for improving sensorineural hearing |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| US20230190863A1 (en) * | 2020-04-22 | 2023-06-22 | Code Pharma B.V. | Pharmaceutical compositions and anti-viral uses thereof |
| IL301688A (en) * | 2020-10-19 | 2023-05-01 | Oak Hill Bio Ltd | Compositions suitable for use in neonates |
| KR20230145397A (ko) * | 2021-02-12 | 2023-10-17 | 뉴렌 파마슈티컬즈 리미티드 | 프라더-윌리 증후군의 치료 |
| JP2024541558A (ja) * | 2021-11-26 | 2024-11-08 | ジェネクシン・インコーポレイテッド | Ｈｇｈ融合タンパク質の高濃度投与剤形 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5374620A (en) | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
| US5681814A (en) * | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
| DK0652766T4 (da) * | 1992-07-31 | 2008-06-09 | Genentech Inc | Vandigt præparat indeholdende humant væksthormon |
| US6207640B1 (en) * | 1994-04-07 | 2001-03-27 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| KR19980701351A (ko) * | 1995-01-13 | 1998-05-15 | 슈타르 피아 | 성장호르몬 및 Ｘ-Ｌｙｓ를 함유하는 안정화된 약제조제물(A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND X-Lys |
| US6767892B1 (en) * | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| WO1999024062A1 (en) | 1997-11-07 | 1999-05-20 | Chiron Corporation | Novel igf-i composition and its use |
| PL353238A1 (en) * | 1999-07-12 | 2003-11-03 | Grandis Biotech Gmbh | Growth hormone formulations |
| HUP0203133A3 (en) * | 1999-10-04 | 2005-07-28 | Chiron Corp Emeryville | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| PT1946776T (pt) * | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| AR040529A1 (es) * | 2002-07-09 | 2005-04-13 | Grandis Biotech Gmbh | Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol |
| ES2532089T3 (es) * | 2005-06-02 | 2015-03-24 | Ipsen Biopharmaceuticals, Inc. | GH e IGF-1 para el tratamiento de trastornos del crecimiento |
| PL3225233T3 (pl) * | 2005-11-01 | 2019-12-31 | Wyeth Llc | Roztwór chlorku sodu do odtwarzania leku |
| CN101505789A (zh) * | 2006-07-06 | 2009-08-12 | 株式会社大熊 | 稳定的人生长激素液体制剂 |
| CN102089319B (zh) * | 2008-05-08 | 2013-11-13 | 味之素株式会社 | 蛋白质的重折叠方法 |
-
2010
- 2010-11-17 KR KR1020127015526A patent/KR101614983B1/ko not_active Expired - Fee Related
- 2010-11-17 CN CN201080052050.4A patent/CN102665691B/zh not_active Expired - Fee Related
- 2010-11-17 US US13/513,858 patent/US20120270782A1/en not_active Abandoned
- 2010-11-17 UA UAA201207340A patent/UA108994C2/uk unknown
- 2010-11-17 EP EP10784450.8A patent/EP2501367B1/en not_active Not-in-force
- 2010-11-17 CA CA2780554A patent/CA2780554C/en not_active Expired - Fee Related
- 2010-11-17 AU AU2010321225A patent/AU2010321225B2/en not_active Ceased
- 2010-11-17 MX MX2012005195A patent/MX2012005195A/es active IP Right Grant
- 2010-11-17 BR BR112012011539A patent/BR112012011539A8/pt not_active Application Discontinuation
- 2010-11-17 JP JP2012539223A patent/JP6084036B2/ja not_active Expired - Fee Related
- 2010-11-17 RU RU2012124985/15A patent/RU2558821C2/ru not_active IP Right Cessation
- 2010-11-17 IN IN2861DEN2012 patent/IN2012DN02861A/en unknown
- 2010-11-17 WO PCT/EP2010/006996 patent/WO2011060922A1/en active Application Filing
- 2010-11-17 ES ES10784450.8T patent/ES2532007T3/es active Active
-
2015
- 2015-10-30 JP JP2015215192A patent/JP6143827B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-30 US US15/281,361 patent/US20170143834A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010321225B2 (en) | 2015-12-03 |
| RU2558821C2 (ru) | 2015-08-10 |
| KR20120104251A (ko) | 2012-09-20 |
| EP2501367A1 (en) | 2012-09-26 |
| KR101614983B1 (ko) | 2016-04-22 |
| US20170143834A1 (en) | 2017-05-25 |
| JP2013510893A (ja) | 2013-03-28 |
| CA2780554A1 (en) | 2011-05-26 |
| JP6143827B2 (ja) | 2017-06-07 |
| JP6084036B2 (ja) | 2017-02-22 |
| RU2012124985A (ru) | 2013-12-27 |
| HK1175711A1 (en) | 2013-07-12 |
| CA2780554C (en) | 2017-08-15 |
| UA108994C2 (uk) | 2015-07-10 |
| AU2010321225A1 (en) | 2012-06-07 |
| CN102665691B (zh) | 2015-05-27 |
| JP2016020395A (ja) | 2016-02-04 |
| EP2501367B1 (en) | 2015-01-21 |
| ES2532007T3 (es) | 2015-03-23 |
| WO2011060922A1 (en) | 2011-05-26 |
| US20120270782A1 (en) | 2012-10-25 |
| CN102665691A (zh) | 2012-09-12 |
| MX2012005195A (es) | 2012-06-12 |
| BR112012011539A2 (pt) | 2016-06-28 |
| BR112012011539A8 (pt) | 2017-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02861A (enrdf_load_stackoverflow) | ||
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| PH12016500216A1 (en) | Stable pharmaceutical composition and methods of using same | |
| EP3626253A3 (en) | Stable formulations of linaclotide | |
| WO2010079468A3 (en) | Delivery particle | |
| WO2010084480A3 (en) | Delivery particles | |
| WO2010079467A3 (en) | Delivery particles | |
| WO2010079466A3 (en) | Delivery particles | |
| PL2081547T3 (pl) | Postać galenowa do podawania składników czynnych poprzez śluzówkę | |
| MX2011012122A (es) | Derivados de tiofeno. | |
| WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
| MY153976A (en) | Lh liquid formulations | |
| MX2011011511A (es) | Sal de abt-263 y fomas en estado solido de la misma. | |
| WO2010092090A3 (en) | Novel salts of sitagliptin | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| WO2011062437A3 (ko) | 고나도트로핀 방출 호르몬 수용체 길항제, 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
| WO2008112368A3 (en) | Phenylalkylcarboxylic acid delivery agents | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| WO2007113202A8 (en) | Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists | |
| WO2012128582A3 (en) | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| MX2012007999A (es) | Compuestos estables de la hormona de crecimiento. | |
| WO2010049449A3 (en) | Novel salts of sunitinib | |
| WO2012075015A3 (en) | Oral metronidazole pharmaceutical compositions | |
| MX2009007265A (es) | Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion. | |
| MX2011007736A (es) | Compuestos de hormona del crecimiento estables. |